Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Strategic Diagnostics Announces Progress in Advancing Clinical Biomarker Discovery
Successful Application of Technology in Cancer Biomarker Identification at M.D. Anderson Cancer Center
Strategic Diagnostics Inc. (Nasdaq:SDIX) – today announced progress in collaborating with the Kleberg Center for Molecular Markers at The University of Texas M. D. Anderson Cancer Center. The center is currently testing SDI’s Genomic Antibody Technology™ (GAT) platform in oncology biomarker discovery research.
SDI’s sequence-based GAT platform triggers the immune system of the host to produce an antibody against a native protein. Through internal and third party analysis, these antibodies have demonstrated superior performance in the recognition and targeting of native protein targets in experimental models and clinical samples as compared to reagents made with traditional methods.
Participating in a collaborative study, independent researchers at M. D. Anderson have now used SDI’s growing library of GAT antibodies to screen hundreds of clinical cancer biopsy samples in a high throughput system to analyze the differential presence of proteins in the tissue samples. The individual protein signature of these samples created with SDI’s reagents allows further research into the clinical significance of the findings. The correlation of the data with the corresponding disease state represented by the samples is focused on yielding new tools to improve diagnostic, prognostic, and patient monitoring decisions.
Matthew H. Knight, SDI’s President and Chief Executive Officer, stated, “As demonstrated in the performance of our antibodies in the M. D. Anderson cancer screens, the fundamental advantages of Genomic Antibody Technology™ clearly benefits the pace, scope, and precision of modern biomarker discovery. We are encouraged by these results and are confident the next phase of the offering’s commercial expansion will further enable our scientists, collaborators and customers in their efforts toward advancing the discovery and understanding of significant protein patterns in human health.”
Strategic Diagnostics offers custom service access to the Genomic Antibody Technology™ platform in polyclonal and monoclonal products as well as a rapidly expanding portfolio of Catalog Reagents targeting cancer markers. These offerings complement SDI’s breadth of traditional antibody development/production services and clinical diagnostic products.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable “return on investment” by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company’s established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.
This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
Strategic Diagnostics Inc.
Stan Fronczkowski
Chief Financial Officer
302-456-6789
www.sdix.com
or
Investor Contact:
Hayden Communications
Brett Maas
646-536-7331
brett@haydenir.com
Source: Business Wire (October 25, 2007 - 7:58 AM EDT)
News by QuoteMedia
www.quotemedia.com
Nice work in the ibox!!! I love it!
I just sold a little to cover my investment...
I'm amazed at this PPS! Its looks like we just had some profit taking and should start going up again for today. SDIX, ONT, and AIDO... I guess I picked them right! Now all I need is AMHI to start growing wings.
I thought SDIX would have taken a bit longer to get up to 5.50 (like mid year). Maybe we will be a 6.50 stock when this is all over!
Raggs;
Coming back from Monterey last weekend, we caught the train in Salinas. Many of the newspapers we saw were in spanish, but the one word in the very large headline, "E.coli", was blaring. Salinas was were the E'coli tainted spinach was recently traced to. Very big news to the workers it looked like.
Still though I like the antibody business better than their testing stuff.
Raggs;
Coming back from Monterey last weekend, we caught the train in Salinas. Many of the newspapers we saw were in spanish, but the one word in the very large headline, "E.coli", was blaring. Salinas was were the E'coli tainted spinach was recently traced to. Very big news to the workers it looked like.
Still though I like the antibody business better than their testing stuff.
Me too!!! I found this company around the time of the sonomi, and was going to sell as quick profit back then. Just as you, once I read about this company I felt it was a keeper!
Very pleased with what I did so far!
Yes, I do a lot of short term trading, but I have had SDIX for years and expect to hold for much longer. They have a tremendous amount of science and going into ever more interesting business segments. Technicals look terrific too - stars se4em to be lining up.
Things still look pretty good! Hope we keep going up this week. From what I can see so far, I think we will!
things still look pretty good today! Are you still in?
SDIX has an estore now...charts have been climbing over the long term too. Not sure if you are still around of it you are in..
http://www.sdix.com/saleslocator.htm
Strategic Diagnostics Reports Fourth Quarter and Full Year 2006 ResultsLast update: 3/1/2007 4:02:29 PM2006 Sales Increase 2.7%; Fourth Quarter Sales Increase by 18.6% over Prior Year NEWARK, Del., Mar 01, 2007 (BUSINESS WIRE) -- Strategic Diagnostics Inc. (SDIX) - a leading provider of antibody products and analytical test kits for a broad range of food, water, agricultural, industrial, environmental and scientific applications, today reported financial results for the fourth quarter and year ended December 31, 2006. Revenues for the year ended December 31, 2006 increased 2.7% to $25.5 million, compared to $24.9 million for the same period in 2005. For the fourth quarter of 2006, revenues increased 18.6% to $7.0 million, compared to $5.9 million in the fourth quarter of 2005. Revenues in the fourth quarter of 2006 were positively impacted by higher sales of agricultural and antibody products. Gross profit (defined as total revenues less manufacturing expenses) for 2006 totaled $13.8 million, as compared to $13.4 million for 2005. Gross margins were 54.1% for both 2006 and 2005. For the fourth quarter of 2006, gross profit increased 32.0% to $3.9 million, compared to $3.0 million for the same period in 2005. The gross margin for the fourth quarter of 2006 was 55.8%, compared to 50.2% for the same period in 2005. For the year ended December 31, 2006, operating expenses increased 3.2% to $24.9 million, compared to $24.2 million in 2005. Operating expenses for the fourth quarter of 2006 increased 3.1% to $6.5 million compared to $6.3 million for the fourth quarter of 2005. For the year ended December 31, 2006, pre-tax income totaled $966,000 compared to $880,000 for 2005. The Company is not reporting a final net income amount on either an aggregate or per share basis at this time, as it is currently finalizing the accounting treatment for deferred tax items. It is expected that the accounting treatment will be finalized within a week. The Company is reporting at this time that it expects that for the year ended December 31, 2006, net income will be in a range from $588,000 to $678,000. Any net income amount in that range will equate to net income per diluted share of $0.03. For the year ended December 31, 2005, net income was $584,000 or $0.03 per diluted share. Diluted shares totaling 20.1 million and 19.9 million were used in the computations for the years 2006 and 2005, respectively. For the fourth quarter of 2006, pre-tax income totaled $650,000, compared to pre-tax loss of $287,000 for the same period in 2005. Net income in the fourth quarter of 2006 is expected, pending resolution of the accounting issue discussed above, to be in a range from $395,000 to $485,000. Any income in that range will equate to net income per diluted share of $0.02. For the fourth quarter of 2005, the Company had a net loss of $292,000, or $0.01 per diluted share. Diluted shares utilized in these computations were 20.2 million and 19.9 million for the fourth quarter of 2006 and 2005, respectively. Matthew H. Knight, the Company's President and Chief Executive Officer, commented, "The 18.6% increase in fourth quarter sales was consistent with our expectations for improving performance across all of the product lines. We are particularly pleased with the 24.2% improvement in our antibody sales versus the fourth quarter of 2005. Also contributing to our sales performance in the quarter was improved performance in a number of legacy product lines, including a 14% improvement in our U.S. water quality product line versus the same quarter in 2005, and a 29% improvement in U.S. agricultural revenue associated with the recovery of business which had been lost to competition in 2005." Mr. Knight continued, "We were disappointed in the sales of our food pathogen products in the fourth quarter. This product line grew 11% during the quarter which is well below our expectations. However, the commercial launch of our new RapidChek(R) SELECT(TM) for Salmonella is being well received, and as we anticipated, the superior performance of this test, along with its complementary format to RapidChek(R) Listeria is driving new sales of both products. In addition, we are working to identify and train new distributors. We expect our sales of food pathogen products to regain strong sales momentum throughout 2007." Food Safety Products For the year ended December 31, 2006, food safety revenues were $9.21 million, compared to $8.98 million for 2005, an increase of 2.6%. Food safety revenues were $2.79 million in the fourth quarter of 2006, compared to $2.3 million in the fourth quarter of 2005, an increase of 21.1 %. Water and Environmental Products Water and environmental products revenue increased 1.2% to $5.20 million for the year ended December 31, 2006, compared to $5.14 million for 2005, and increased 2.2% to $1.22 million for the fourth quarter of 2006, compared to $1.19 million for the same quarter in 2005. Antibody Products Antibody revenues increased 3.5% to $11.10 million in the year ended December 31, 2006, compared to $10.72 million for 2005. Revenues also increased 24.2% to $2.98 million for the fourth quarter of 2006, compared to $2.40 million for the same quarter in 2005. Balance Sheet The Company completed the quarter ended December 31, 2006 with $10.90 million in cash compared to $10.0 million as of December 31, 2005. Conference Call A conference call to review fourth quarter results is scheduled for 4:30 p.m. March 1, 2007. The dial-in number for the live conference call will be 877-407-8031 (201-689-8031 outside the U.S.). A live webcast of the conference call will be available on the Company's website, , as well as . For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. Eastern-time on March 1, 2007 through 11:59 p.m. on March 2, 2007. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 232636. About Strategic Diagnostics Inc. Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market. This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project" "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited) Three Months Twelve Months Ended December 31, Ended December 31,-------------------------------------------- ------------------------- 2006 2005 2006 2005-------------------------------------------- ------------------------- Revenues $ 6,990 $ 5,896 $ 25,522 $ 24,845------------------------------- ------------ ------------ ------------ Total net revenues 6,990 5,896 25,522 24,845------------------------------- ------------ ------------ ------------OPERATING EXPENSES: Manufacturing 3,088 2,939 11,721 11,416 Research and development 671 712 2,630 3,034 Selling, general and administrative 2,692 2,609 10,591 9,722------------------------------- ------------ ------------ ------------ Total operating expenses 6,451 6,260 24,942 24,172------------------------------- ------------ ------------ ------------ Operating income (loss) 539 (364) 580 673Interest income, net 111 77 386 207------------------------------- ------------ ------------ ------------Income (loss) before taxes 650 (287) 966 880------------------------------- ------------ ------------ ------------Shares used in computing basic net income (loss) per share 20,141,000 19,924,000 20,032,000 19,741,000------------------------------- ------------ ------------ ------------Shares used in computing diluted net income (loss) per share 20,227,000 19,924,000 20,109,000 19,870,000------------------------------- ------------ ------------ ------------SOURCE: Strategic Diagnostics Inc.
Strategic Diagnostics Inc.Company Contact:Stan Fronczkowski, 302-456-6789orInvestor Contact:Hayden CommunicationsBrett Maas, 843-272-4653brett@haydenir.comorMatt Hayden, 843-272-4653matt@haydenir.comCopyright Business Wire 2007 ********************************************************************** As of Sunday, 02-25-2007 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 12-12-2006 for SDIX @ $3.76. For more information on Comtex SmarTrend® Alert, contact your market data provider or go to SmarTrend is a registered
Strategic Diagnostics Sees Yr Net $588,000-$678,000 >SDIX
Strategic Diagnostics to Report Fourth Quarter and Fiscal Year 2006 Results on March 1, 2007Last update: 2/23/2007 10:28:00 AMNEWARK, Del., Feb 23, 2007
Strategic Diagnostics Inc. (SDIX) a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, expects to release its fourth quarter and fiscal year 2006 results at approximately 4 p.m. ET on Thursday, March 1, 2007. The Company has scheduled an investor conference call for 4:30 p.m. ET on the same day. The dial-in number for the live conference call will be 877-407-8031 (201-689-8031 outside the U.S.). A live webcast of the conference call will be available on the Company's website, , as well as . For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on March 1, 2007 through 11:59 p.m. on March 2, 2007. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 232636. About Strategic Diagnostics Inc. Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market. This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
raggs; News today pushed SDIX into a bullish P&F chart pattern. First time since 04, so might be a turning point. Doesn't matter to me which way it goes as I will buy more if it goes down.
Nice couple of news releases and I suspect more to come!
natvik
Strategic Diagnostics Names Beijing Green Science and Technology as Exclusive Distribution Partner for Water Quality Tests in ChinaLast update: 2/8/2007 11:37:12 AMNEWARK, Del., Feb 08, 2007 (BUSINESS WIRE) -- Strategic Diagnostics Inc. (SDIX) - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, and the Beijing Green Science and Technology Company today recognized the successful completion of their first year of collaboration and confirmed that Beijing Green will continue to be the exclusive distribution partner for the Microtox(R) and Deltatox(R) rapid toxicity systems in China. The two companies initiated their relationship in 2005, with 2006 being the first full year of promoting the technology in China. Throughout the year, both companies worked to inform national and local government and regulating agencies, as well as industry, of the Microtox(R) applications for the monitoring of drinking water safety and water quality. Sales in China exceeded $250,000 in 2006 and are expected to double in 2007. Matt Knight, CEO and President of Strategic Diagnostics Inc. commented, "By working closely with Beijing Green, we have met all our financial and project milestones, laying the foundations for a successful long-term partnership. It is our intention to continue this cooperation to ensure that Chinese industry has access to the best water testing technology available." Dr. Yongsheng Chen, the President of Beijing Green and Science Technology Company, praised the partnership between the two companies. "Through joint efforts with SDI, we are achieving rapid customer acceptance and are now recognized as the leading toxicity testing technology provider in China," Mr. Chen added. "Besides successfully achieving our financial goals, we are receiving appreciation from a growing number of Chinese industries for helping them cope with their mounting environmental challenges." As Chinese industry goes through an unprecedented period of expansion, it faces the challenge of balancing economic growth with the protection of its environment. This will only be possible with a thorough and modern system for the monitoring of the impact on its rivers and coastal areas, and the use of this information to implement required controls in adherence to government regulation. The Microtox(R) and Deltatox(R) methods and test systems for the rapid detection of water toxicity are the most widely used rapid toxicity assays in the world. In January 2006, the methods gained U.S. Department of Homeland Security designation as an anti-terror technology and are widely used to protect drinking water supplies for municipalities, government buildings, and other locations or entities with large concentrations of people, such as the Olympics. SDI and its distribution partners also continue to support application of the methods in food production, noting that water is often the largest single ingredient in food manufacturing, and is largely untested by the industry. In addition, the technology is widely used around the world for the monitoring of industrial and municipal effluent. Unlike chemical analysis for specific compounds, toxicity testing looks at the cumulative and synergistic effects, in water, of all the different contaminants from diverse sources and quantifies their potential impact on the ecosystem. More than 600 publications have shown that the Microtox(R) assay is an appropriate and uniquely practical test giving quantitative results in minutes. About Beijing Green Beijing Green Science and Technology Company, a leading environmental technology provider, dedicates itself to the development and promotion of state of the art environmental products, water treatment process monitoring and optimization technologies, and monitoring system integration in China. With strong technical backgrounds, it has established close cooperations with major Chinese governmental agencies, national labs, academic institutions, and industries. Throughout the past four years, Beijing Green has experienced rapid growth and market expansion. It now has a sales network covering 40 major Chinese cities. About Strategic Diagnostics Inc. Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market. This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project" "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission. SOURCE: Strategic Diagnostics Inc. Strategic Diagnostics Inc.Company Contact:Stan FronczkowskiChief Financial Officer302-456-6789orInvestor Contact:Hayden CommunicationsBrett Maas (brett@haydenir.com)646-536-7331Copyright Business Wire 2007 ********************************************************************** As of Sunday, 02-04-2007 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 12-12-2006 for SDIX @ $3.76. For more information on Comtex SmarTrend® Alert, contact your market data provider or go to SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright © 2004-2007 Comtex News Network, Inc. All rights reserved.
Strategic Diagnostics (SDIX) Announces Successful Expansion of Proprietary Antibody Technology
01-30-2007 08:27:24 AM
More Corporate News
Foster Wheeler (FWLT) Subsidiary Awarded Contract Worth Approx. $200 Million
Tetra Tech (TTEK) Wins MSAs Valued at up to $20 Million to Help Cincinnati Control CSOs and SSOs
Tetra Tech (TTEK) Awarded $20M Contract for Cincinnati Work
Nestor Traffic Systems (NEST) Awarded 2-Year Contract with Diboll, Texas
DreamWorks Animation (DWA) and Aardman Animations End Multi-Picture Deal
Strategic Diagnostics Inc. (Nasdaq: SDIX) announced that its partnership with the Oriental Yeast Company is meeting commercialization targets for its Genomic Antibodies service offering within the Japanese Life Science industry.
"We are pleased with the initial effort of OYC's Life Sciences team and the growing momentum in building demand for custom polyclonal and monoclonal antibodies using our Genomic Antibodies(TM) technology platform," commented Matt Knight, President and CEO of Strategic Diagnostics. "With about 12 weeks now under our belt, we feel confident that OYC will continue to see adoption of the Genomic Antibodies platform, consistent with their sales projections."
Genomic Antibodies technology generates novel antibody reagents faster, more cost effectively, and without the need for purified protein or peptide. Customers only need to supply genetic sequence of their protein of interest electronically to begin generating a custom antibody project.
Lots of acquiring going on!
Form Formats Description Filing Date File/Film No
4 [html][text] 4 KB Statement of changes in beneficial ownership of securities
Acc-no: 0001125282-07-000040 2007-01-03
4 [html][text] 4 KB Statement of changes in beneficial ownership of securities
Acc-no: 0001125282-07-000038 2007-01-03
4 [html][text] 4 KB Statement of changes in beneficial ownership of securities
Acc-no: 0001125282-07-000036 2007-01-03
4 [html][text] 5 KB Statement of changes in beneficial ownership of securities
Acc-no: 0001125282-07-000032 2007-01-03
4 [html][text] 4 KB Statement of changes in beneficial ownership of securities
Acc-no: 0001125282-07-000030 2007-01-03
4 [html][text] 5 KB Statement of changes in beneficial ownership of securities
Acc-no: 0001125282-07-000028 2007-01-03
DJ Strategic Diagnostics Names Fronczkowski As Fincl Chief
01/16/2007
Dow Jones News Services
(Copyright © 2007 Dow Jones & Company, Inc.)
DOW JONES NEWSWIRES
Strategic Diagnostics Inc. (SDIX) named Stan Fronczkowski chief financial officer effective Jan. 15.
The Newark, Del., developer of biotechnology-based detection products previously announced Anthony Simonetta's resignation to pursue other opportunities.
Strategic Diagnostics said Fronczkowski was most recently vice president for finance, Asia-Pacific, at Keystone Foods Corp.
-Veronica Dagher; 201-938-5400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
01-16-07 1023ET
Copyright (c) 2007 Dow Jones & Company, Inc.
StockProfiler.US: Third Largest Overseas Acquisition Worth $90 Million
10:32a ET November 7, 2006 (Comtex)
Pacific Corporation (NASDAQ: APFC); KMG Chemicals Inc (NASDAQ: KMGB); Strategic Diagnostics Inc. (NASDAQ: SDIX); Nevada Chemicals Inc (NASDAQ: NCEM); American Mace Security International, Inc. (NASDAQ:MACE); Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA)
Sign up for your Free Stock and Updated news subscription today at http://www.stockprofiler.us . CEO's who want to effectively broadcast their company's progress are urged to contact Stockprofiler.US at 603-424-9068 or 603-424-5534. Our staff will be happy to explain how we can help you get your message out to a targeted audience.
Reported October 18, 2006 S Kumars is acquiring American Pacific, a US home furnishing maker and distributor, for around $90 million (Rs 405 crore), nudging past a few Chinese companies and private equity funds, sources close to the development said.
While S Kumars CEO Nitin Kasliwal said "No comments" on the deal, sources said a company announcement on the deal is likely by the month end. ET had earlier reported that S Kumars was bidding for American Pacific.
This is the third largest overseas acquisition in the home textile space in less than a year. The other two are GHCL's acquisition of UK's home furnishing retail chain Rosebys, and American textile company Dan River. Besides this, Welspun and Alok Industries have also bought businesses abroad. Sources say many acquisitions are in the pipeline as companies are put on the block abroad.
American Pacific Corporation closed at $7.92 Monday, trading 20,640 shares.
About American Pacific Corporation (NASDAQ: APFC) American Pacific is a chemical and aerospace company with the following products: (i) fine chemicals in the form of active pharmaceutical ingredients and registered intermediates, (ii) perchlorate chemicals used in space propulsion and other applications, (iii) liquid in-space propellant thrusters used for attitude control on satellites, (iv) Halotron, a clean fire extinguishing agent, (v) sodium azide and other energetic products used in various applications and (vi) water treatment equipment. Additional information about American Pacific can be obtained by visiting the Company's web site at www.apfc.com.
KMG Chemicals Inc. closed at $9.18 Monday, trading 3,400 shares.
About KMG Chemicals Inc. (NASDAQ: KMGB)
KMG Chemicals, Inc., through its subsidiaries, produces and distributes specialty chemicals to carefully focused markets. The Company grows by acquiring and optimizing stable chemical product lines and businesses with established production processes. KMG's operations are focused on wood treatment chemicals, animal health products and agricultural chemicals. For more information, visit the Company's web site at www.kmgchemicals.com.
Strategic Diagnostics Inc. closed at $3.44 Monday, trading 30,274 shares.
About Strategic Diagnostics Inc. (NASDAQ: SDIX)
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. For more information visit www.sdix.com
Nevada Chemicals Inc. closed at $8.43 Monday, trading 10,100 shares.
About Nevada Chemicals Inc. (NASDAQ: NCEM) Nevada Chemicals is the premier producer of strategic chemicals for the gold mining industry of the United States. Nevada Chemicals is headquartered in Salt Lake City, Utah and its shares trade on the Nasdaq market under the symbol NCEM. We are strategically located to produce and deliver liquid sodium cyanide to Western U.S. based precious metal mining concerns.
Mace Security International, Inc. closed at $2.50 Monday, trading 22,000 shares.
About Mace Security International, Inc. (NASDAQ:MACE) Mace Security International, Inc. (NASDAQ: MACE) is a public company trading on the NASDAQ National Market System under the symbol MACE. The Company owns the highly recognized name Mace, which is known for manufacturing and marketing high quality security products including personal defense sprays, home and business surveillance and security, automotive security and child safety and security. Mace also owns and operates car and truck washes throughout the United States. The company's web site address is http://mace.com.
Teva Pharmaceutical Industries Ltd. closed at $33.30 Monday, trading 6,440,429 shares.
About Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA)
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. For more information visit www.tevapharm.com.
Disclaimer StockProfiler.us or any of its assets or any principles, partners, or agents are not, nor do we represent ourselves to be, registered investment advisers, brokers, or dealers. Readers should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the advertised Company(s).
It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Readers should not rely solely on the information contained in this website, but should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the companies herein represented. All viewers should read the full disclaimer at www.stockprofiler.us The Companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stockprofiler.US affiliates are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
Strategic Diagnostics to Report Third Quarter Results on November 2, 2006advertisementRelated information E-mail this article Print-friendly versionStocks mentioned in this articleStrategic Diagnostics Inc.(SDIX) Quote, Chart, News Related topicsEarnings Reports
All Business Wire NewsStrategic Diagnostics Inc. SDIX a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, expects to release its third quarter results at approximately 4 p.m. ET on Thursday, November 2, 2006. The Company has scheduled an investor conference call for 4:30 p.m. ET on the same day.
Related newsNintendo Says 1st-Half Profit Up 48 Pct.Nissan Profit Surges 31 PercentDow, Nasdaq Close Higher on Fed DecisionAftermarket Movers: Affymetrix GainsGM, Adobe, Among Wall Street's Movers
The dial-in number for the live conference call will be 877-407-8031 (201-689-8031 outside the U.S.). A live webcast of the conference call will be available on the Company's website, www.sdix.com, as well as www.vcall.com. For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on November 2, 2006 through 11:59 p.m. on November 3, 2006. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 218169.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.
This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
Contact Information: Strategic Diagnostics Inc. Anthony J. Simonetta, 302-456-6789 www.sdix.com or Investor Contact: Hayden Communications, Inc. Matt Hayden/Brett Maas 843-272-4653 brett@haydenir.com
© 2006 BusinessWire
Back to Recent News
Strategic Diagnostics Inc. Announces NPIP Technical Approval and First Commercial Orders for RapidChek(R) SELECT(TM) SalmonellaadvertisementRelated information E-mail this article Print-friendly versionStocks mentioned in this articleStrategic Diagnostics Inc.(SDIX) Quote, Chart, News
All Business Wire NewsStrategic Diagnostics Inc. SDIX, today announced that their new RapidChek(R) SELECT(TM) Salmonella testing product has been approved by the Technical Committee of the National Poultry Improvement Plan (NPIP) as an analytical method for the detection of Salmonella species in NPIP samples. The method was approved at the NPIP 38th Biennial Meeting held in Portland, Oregon. The Company also announced full commercial adoption of the method by four food processing companies within the first four weeks of commercialization, each with an average annual account value of $50,000.
Recent investing newsZacks Challenge Top Player Interview features Acorda Therapeutics, BE Aerospace, Research In Motion Ltd., Optimal Group and Medifast Inc.Stolt-Nielsen S.A. Reports Results for Third Quarter and Nine Months 2006Amdocs Statement: Company in Good Position as Vodafone Selects Finalists for a Major Managed Services ProjectRyanair Launches Bid for Aer LingusFirst Charter Announces Key Changes in Executive Leadership
Adoption of the method by NPIP is a strong endorsement of performance attributes of the RapidChek(R) SELECT(TM) Salmonella product. The NPIP is a cooperative Federal-State-Industry program developed for controlling certain poultry diseases. NPIP consists of a variety of programs intended to prevent and control egg-transmitted, hatchery-disseminated poultry diseases. One such program is monitoring environmental samples for the detection of Salmonella species in poultry hatcheries.
NPIP samples tend to be high in non-Salmonella, background bacteria, which interferes in the performance of many rapid detection methods that compete with SDI's RapidChek(R) SELECT(TM) Salmonella. These interferences produce costly, high "false positive" results not seen with the SDI method. In addition to the NPIP approval, the SELECT(TM) technology will be added to Title 9 of the Code of Federal Regulations, Section 147.12(b)(3).
"Strategic Diagnostics invented the SELECT(TM) technology as a result of direct input from NPIP and other customers experiencing test specificity and sensitivity issues in their Salmonella testing programs. Its ability to generate exceptionally accurate results in the most challenging samples, and to do so in a highly cost effective manner, continues to earn us new business opportunities and industry recognition," commented Matthew Knight, President and CEO of SDI. The NPIP market segment for SDI has an estimated value of $6MM dollars, and the overall domestic Salmonella market has been estimated at $74MM annually.
Commenting on the first commercial wins for the new product, Mr. Knight added, "We are excited that within the first month of commercialization we have begun to see uptake in the commercial food manufacturing markets we have targeted. Converting four new accounts, all taken from competition, is a clear indication that RapidChek(R) SELECT(TM) Salmonella is succeeding in delivering more value than the competitive offering. Today's announcement is another example of how SDI's focus on the customer is guiding our innovation and enabling us to deliver high value products to important markets like food safety."
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.
This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
Contact Information: Strategic Diagnostics Inc. Anthony J. Simonetta, 302-456-6789 www.sdix.com or Investor Contact: Hayden Communications Brett Maas, 646-536-7331 brett@haydenir.com
© 2006 BusinessWire
Back to Recent News
Strategic Diagnostics to Present at Noble Research's ''OnTrack 06'' Small Cap Conference on September 27, 2006advertisementRelated information E-mail this article Print-friendly versionStocks mentioned in this articleStrategic Diagnostics Inc.(SDIX) Quote, Chart, News
All Business Wire NewsStrategic Diagnostics Inc. SDIX - announced today that Matthew Knight, President and Chief Executive Officer, will present at Noble Research's "OnTrack 2006" Small Cap Conference and Microcap Symposium at the Ballantyne Spa and Golf Resort in Charlotte, North Carolina. The Company will present at 9:15 a.m. on September 27 in the Darlington Room on the main floor of the convention concourse and the presentation will be webcast live and archived for 30 days at the conference's website, www.ontrack06.com.
Related newsStrategic Diagnostics Announces New Agreement to Supply Diagnostic Antibody Reagents
During the presentation, Mr. Knight will discuss the recent contract wins for Genomic Antibodies(TM), which have positioned SDI as an emerging leader in the production of monoclonal antibodies and the recently launched RapidChek(R) SELECT(TM) Salmonella product that now complements SDI's industry-leading food pathogen testing kits. Mr. Knight will highlight several new initiatives including SDI's recently announced contract with the Broin Companies, the second-largest producer of ethanol in the industry, in which SDI's patent-pending expertise is used to increase efficiency in the production of ethanol.
Following the formal presentation, SDI will have two breakout sessions, one in the Martinsville Room on the lower floor of the convention concourse at 9:45 a.m. and an alternate breakout session on September 26 at 2:15 p.m. in Small Cap Pit #3 on the main floor. SDI management will be available for one-on-one meetings throughout the day, which may be arranged by emailing Noble Research at info@ontrack06.com.
About Noble Research/the OnTrack 2006 Conference
Noble Financial supports emerging growth companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble's equity conferences allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The goal is to deliver outstanding business organization, world-class accommodation & meeting facilities, and memorable social events.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.
I've been invested with this company for a couple years now and figured I'd start up a board. If you read the history on this company and what they have gone through...they will make it and do very well over the next few years... my opinion, but an educated one.
Very interesting concept I must say! I'll add it to my radar list.
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
77
|
Created
|
09/13/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |